Novel Therapies and Strategies for Treating Patients With Myeloproliferative Neoplasms
At the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Winter Symposium in Miami, Florida, Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses novel therapies and new strategies for treating patients with myeloproliferative neoplasms (MPN).
Transcript:
Hi, my name is Gabby Hobbs and I'm the clinical director of the Leukemia Service at the Mass General Hospital in Boston. I'm an associate professor at Harvard Medical School. I'm thrilled to be here at the LL&M Winter Symposium where I'm going to be talking about myeloproliferative neoplasms.
For my talk, I'll be discussing updates in the management of patients with MPNs, and I'll also discuss a lot of the novel therapies that are being developed. First, I'll talk about essential thrombocythemia and polycythemia vera and review basic things about risk stratification as well as how to treat our patients. But in addition, we'll talk about some new developments for the management of these patients, which include medications that are being developed like rusfertide, for polycythemia vera, and a variety of other agents that are being developed for essential thrombocythemia like bomedemstat, and as well as ropeginterferon, which is also being studied for this group of patients.
In addition to new medications, I'll review some exciting data about the medications that we currently have available for our patients that do more than reduce the risk of thrombosis, but that potentially can modify the disease biology of these conditions by reducing the level of the mutant JAK-2.
Moving on to myelofibrosis, I'll discuss how I approach the management of myelofibrosis initially with diagnosis and then risk stratification. I'll go over the 4 available JAK inhibitors that we have, and then I'll discuss new therapies that were presented at ASH. Initially, I'll talk about medications that are being studied for anemia, with luspatercept being the next one that is most likely to get approved, but there's other agents that are being developed for anemia as well, including a medication called elritercept.
In addition to medications that are being developed for anemia, there's a variety of other medications. A list is almost too long to mention in one talk of agents that are being studied alone, but mostly in combination with JAK inhibitors, with ruxolitinib being the most common for the management of myelofibrosis. Some of these include agents like BET inhibitors, MDM2 inhibitors, telomerase inhibitors, and PIM-kinase inhibitors, among others.
And then in addition to those, there are a few novel agents that include monoclonal antibodies that are targeting the calreticulin mutation specifically, as well as new selective type-2 JAK inhibitors for the management of this disease. Thank you so much.
Source:
Hobbs G. Updates in Myeloproliferative Neoplasms. Presented at Lymphoma, Leukemia & Winter Symposium; February 7-9, 2025. Miami, FL.
